A Randomized Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK1160724 and Tiotropium Bromide.
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Revefenacin (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- 20 May 2009 Actual end date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
- 14 Jul 2008 Results data have been reported in a Theravance media release.
- 21 Apr 2008 Status changed from initiated to completed according to ClincalTrials.gov.